A Meta-Analysis to Evaluate the Risk for Fatigue in Patients Treated with Olaparib for Advanced Cancer
Fatigue and neuropathy were found to be common in patients treated with olaparib, and should be identified and managed early.
A Phase 1b and Randomized Phase 2 Trial of Pazopanib with or Without Fosbretabulin in Advanced Recurrent Ovarian Cancer
Although the combination of 2 antivascular agents showed preliminary efficacy, increased cardiac toxicity has resulted in premature discontinuation of the trial.
The Efficacy of Apatinib Treatment for Advanced Ovarian Cancer After Second-Line Chemotherapy Failure
In a prospective trial, the VEGFR-2 small-molecule inhibitor apatinib has shown promising efficacy and safety signals.
Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy for Recurrent Epithelial Ovarian Cancer
Based on the tolerable safety profile established in phase 1b of the ORION-01 trial, the recommended dose for expansion/recommended phase 2 dose of the oregovomab/nivolumab combination immunotherapy has been established.
Maintenance Olaparib Following Platinum-Based Chemotherapy in Newly Diagnosed Patients with Advanced Ovarian Cancer and a BRCA1/2 Mutation: Results from the Phase 3 SOLO1 Trial
Results from the phase 3 SOLO1 trial demonstrate a substantial, unprecedented improvement in progression-free survival for olaparib versus placebo.
This combination of antiangiogenic and immune checkpoint blockade has clinical activity in women with recurrent ovarian cancer.
Association of PD-L1 Expression with Clinical Response to Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer
Results from the KEYNOTE-100 study show that expression of PD-L1 and inflamed T-cell–associated genes are associated with clinical response in advanced, recurrent ovarian cancer.
A Phase 1/2 Study of Chemo-Immunotherapy with Durvalumab and Pegylated Liposomal Doxorubicin (PLD) in Platinum-Resistant Recurrent Ovarian Cancer
Durvalumab/PLD combination shows promising efficacy and a tolerable safety profile in women with platinum-resistant ovarian cancer.
Early intervention and supportive care for gastrointestinal and hepatic toxicities should be considered for patients receiving PARP inhibitors.
Clinical Characteristics of Ovarian Cancer Relapse in BRCA1/2 Germ-Line Mutation Carriers and Noncarriers
Analysis of high-grade serous ovarian cancers suggests that BRCA1/2-driven cancers have a more favorable mode of relapse than sporadic cancers.